Format

Send to

Choose Destination
J Infect Dis. 2006 Feb 15;193(4):488-93. Epub 2006 Jan 3.

Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapy.

Author information

1
University of Colorado School of Medicine, Denver, 80262, USA. adriana.weinberg@uchsc.edu

Abstract

To define the immune correlates of protection against cytomegalovirus (CMV) end-organ disease, CMV-specific interferon (IFN)- gamma enzyme-linked immunospot (ELISPOT) and CD8(+) and CD4(+) intracellular IFN- gamma synthesis assays were performed for subjects with CD4(+) cell counts of < or =50 cells/ microL who were enrolled in a prospective observational study of CMV infection in the era of highly active antiretroviral therapy. Of 87 subjects, 46 developed viremia, 14 developed end-organ disease, and 20 died. Positive ELISPOT assay results, but not positive results for CD4(+) or CD8(+) intracellular IFN- gamma synthesis, were associated with delayed development of viremia and CMV end-organ disease or death. CMV viremia did not appear to boost CMV-specific immunity. ELISPOT assays may be used to identify HIV-infected patients who might benefit from anti-CMV prophylactic interventions.

PMID:
16425127
DOI:
10.1086/499826
[Indexed for MEDLINE]

Publication type, MeSH terms, Substance, Grant support

Publication type

MeSH terms

Substance

Grant support

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center